Differential effects of pioglitazone on advanced atherosclerotic lesions

American Journal of Pathology

Volumn 175, Issue 3, 2009, Pages 1348-

  Thorp, Edward ^a   Tabas, Ira ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; DRUG EFFECT; LETTER; LIPID DIET; PRIORITY JOURNAL;

EID: 70349243183     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090483     Document Type: Letter

References (5)

1. Nakaya H, Summers BD, Nicholson AC, Gotto AM, Jr., Hajjar DP, Han J: Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPAR{gamma} ligand pioglitazone. Am J Pathol 2009, 174:2007-2014
2. Tabas I: Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005, 25:2255-2264
3. Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I: Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation 2007, 116:2182-2190 (Pubitemid 350060356)
4. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004, 114:1564-1576
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289 (Pubitemid 41416583)